{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jairath NK"],"funding":["National Psoriasis Foundation","Foundation for the National Institutes of Health","Dermatology Foundation"],"pagination":["e0277655"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9668185"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(11)"],"pubmed_abstract":["<h4>Background</h4>Large cell transformation (LCT) of Sezary Syndrome (SS) is a rare phenomenon. To date, there are no rigorous studies identifying risk factors for its development.<h4>Objectives</h4>Here, we seek to characterize the clinicopathologic risk factors that predispose patients with SS to develop LCT.<h4>Methods</h4>We retrospectively evaluated all SS patient records available in the Michigan Medicine Cancer Registry from 2010-2021. Clinical and pathologic variables were compared between groups. The Kaplan-Meier method and log-rank test were used to assess overall survival.<h4>Results</h4>Of 28 SS patients identified, eight patients experienced LCT, and 20 did not (NLCT). Peak lactate dehydrogenase (LDH) before LCT (p = 0.0012), maximum total body surface area (TBSA) involvement"],"journal":["PloS one"],"pubmed_title":["Predictors of large cell transformation in patients with Sezary Syndrome-A retrospective analysis."],"pmcid":["PMC9668185"],"funding_grant_id":["K01-AR072129"],"pubmed_authors":["Bardhi R","Tejasvi T","Hristov AC","Runge JS","Jairath R","Patrick M","Jairath NK","Tsoi LC","Wang Y","Wilcox RA","Bledea R"],"additional_accession":[]},"is_claimable":false,"name":"Predictors of large cell transformation in patients with Sezary Syndrome-A retrospective analysis.","description":"<h4>Background</h4>Large cell transformation (LCT) of Sezary Syndrome (SS) is a rare phenomenon. To date, there are no rigorous studies identifying risk factors for its development.<h4>Objectives</h4>Here, we seek to characterize the clinicopathologic risk factors that predispose patients with SS to develop LCT.<h4>Methods</h4>We retrospectively evaluated all SS patient records available in the Michigan Medicine Cancer Registry from 2010-2021. Clinical and pathologic variables were compared between groups. The Kaplan-Meier method and log-rank test were used to assess overall survival.<h4>Results</h4>Of 28 SS patients identified, eight patients experienced LCT, and 20 did not (NLCT). Peak lactate dehydrogenase (LDH) before LCT (p = 0.0012), maximum total body surface area (TBSA) involvement","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-06-01T01:36:09.434Z","creation":"2025-06-01T01:36:09.434Z"},"accession":"S-EPMC9668185","cross_references":{"pubmed":["36383618"],"doi":["10.1371/journal.pone.0277655"]}}